Evidence map›Paper›PMID 34786342›Full record

ArticleIDCases2021

Vasiliki Kalotychou, Demetrios Mermigkis, Maria G Kanariou, Marianna Tzanoudaki, Vasiliki Epameinondas Georgakopoulou, Irene Kourbeti, George L Daikos

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in IDCases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Vasiliki KalotychouFirst Department of Medicine, National and Kapodistrian University of Athens, Laikon, General Hospital, Greece.
Demetrios MermigkisFirst Pulmonary Department, Sismanogleio General Hospital, Athens, Greece.
Maria G KanariouDepartment of Immunology-Histocompatibility, Specialized Center & Referral Center for Primary Immunodeficiencies-Paediatric Immunology, "Aghia Sophia" Children's Hospital, Athens, Greece.
Marianna TzanoudakiDepartment of Immunology-Histocompatibility, Specialized Center & Referral Center for Primary Immunodeficiencies-Paediatric Immunology, "Aghia Sophia" Children's Hospital, Athens, Greece.
Vasiliki Epameinondas GeorgakopoulouFirst Pulmonary Department, Sismanogleio General Hospital, Athens, Greece.
Irene KourbetiFirst Department of Medicine, National and Kapodistrian University of Athens, Laikon, General Hospital, Greece.
George L DaikosFirst Department of Medicine, National and Kapodistrian University of Athens, Laikon, General Hospital, Greece.
National and Kapodistrian University of Athens · GRChildren's Hospital Agia Sophia · GRSismanoglio General Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The X-chromosome linked (XL) female carriers of chronic granulomatous disease (CGD) are considered to have no risk for infection. Herein we present a female CGD XL-carrier who developed

Indexed as

Chronic Granulomatous DiseaseNeutrophils’ oxidative activityPneumocystis jiroveciiX-chromosome inactivationX-linked carrier

Identifiers

PMID34786342
PMCPMC8577472
OpenAlexW3208470325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.